Ann: Update on AeroForm Availability in US Medical Institutions, page-8

You are correct that management have never put out any forecast. However, they have been complicit in allowing the the Canaccord analyst to continue to put out his 'out of whack' forecasts for at least 1 year. The main covering analyst normally 'works closely' with management when putting out such forecasts for these kind of microcap companies. The management should have at least gently guided him away from such an aggressive forecast. However, they still had a huge CR to do (again which was not predicted anywhere in the Canaccord models) so it wasn't in their interests. A point which is not lost on me and my subsequent diminishing trust in the AXP Board and CEO.

So only once the CR was done and the rubber hit the road with the FDA approval, did management fess up an actual forecast (even then it was prompted by the analyst during the call investor ). This is when we got the hokey stick (exponential) forecast from Dodson. He will now be held to account on this ball park forecast which isn't particularly challenging given the number of sites being signed up.

The SP weakness from May 25 is purely tax loss selling, imo. Low liquidity microcaps which are down over 30-50% over the FY are at the highest risk of heavy tax loss selling. AXP fits this description to perfection. Thus the useless announcement last week to try and shore up the SP for some of those panicked investors.

Maybe 'lower growth pathway' wasn't the right term. More like delayed start to the expected strong take up. Let's hope our expectations are not misplaced.